RedHill Biopharma Files 6-K with Pro Forma Financials

TL;DR

RHBP files 6-K with pro forma financials for Cumberland deal announced Oct 20.

AI Summary

RedHill Biopharma Ltd. filed a 6-K report on December 31, 2025, incorporating unaudited pro forma condensed consolidated financial information. This information relates to definitive agreements previously announced on October 20, 2025, between RedHill Biopharma Ltd. and Cumberland Pharmaceuticals Inc.

Why It Matters

This filing provides updated financial context for the company's previously announced agreements with Cumberland Pharmaceuticals Inc., offering insight into the potential financial implications of this partnership.

Risk Assessment

Risk Level: low — The filing is primarily informational, providing pro forma financial data related to a previously announced agreement, and does not introduce new material risks.

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• Cumberland Pharmaceuticals Inc. (company) — Party to definitive agreements
• October 20, 2025 (date) — Date of previous announcement
• December 2025 (date) — Reporting period for the 6-K

FAQ

Filing Documents

• zk2534156.htm (6-K) — 14KB
• exhibit_99-1.htm (EX-99.1) — 231KB
• 0001178913-25-004156.txt ( ) — 246KB

Forward Looking Statements

Forward Looking Statements The unaudited pro forma condensed consolidated financial information contained in Exhibit 99.1 to this Form 6-K contains "forward-looking "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the potential impact of the strategic transaction with Cumberland Pharmaceuticals Inc. Forward-looking materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation the risk that the strategic transaction with Cumberland will not bring the currently anticipated benefits to the Company or the global Talicia business and the risk that the assumptions made by the Company in preparing the unaudited pro forma condensed consolidated financial information are incorrect. The Company believes such assumptions are reasonable as of the date of this filing; however, such assumptions are inherently uncertain, are subject to change and may be affected by factors beyond the Company's control. As a result, actual results may differ materially from the unaudited pro forma condensed consolidated financial information. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 10, 2025. All f

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: December 31, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR